

AUSTRALIAN

RESEARCH

BLUE BOOK SERIES

Health & Life Science Review

Quarterly

August 2004

Commercialising world class healthcare science

Contents

This is an extract from the August 2004 Quarterly Health & Life Science Review.

IMPORTANT NOTICE

Aegis has been commissioned to produce this report

Disclaimer & Disclosure of Interests

This publication has been prepared by Aegis Equities Research Pty Limited (ACN 085 293 910) ("Aegis"), an Australian Financial Services Licensee. Aegis has been commissioned to prepare this independent research report ("Report") and will receive fees for its preparation. Each company specified in the Report (the "Participants") has provided Aegis with information about its activities. Whilst the information contained in this publication has been prepared with all reasonable care from sources that Aegis believes are reliable, no responsibility or liability is accepted by Aegis for any errors, omissions or misstatements however caused. Any opinions, forecasts or recommendations reflects the judgement and assumptions of Aegis as at the date of publication and may change without notice. Aegis and each Participant in the Report, their officers, agents and employees exclude all liability whatsoever, in negligence or otherwise, for any loss or damage relating to this document to the full extent permitted by law. This publication is not and should not be construed as, an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. Any opinion contained in the Report is unsolicited general information only. Neither Aegis nor the Participants are aware that any recipient intends to rely on this Report or of the manner in which a recipient intends to use it. In preparing our information, it is not possible to take into consideration the investment objectives, financial situation or particular needs of any individual recipient. Investors should obtain individual financial advice from their investment advisor to determine whether opinions or recommendations (if any) contained in this publication are appropriate to their investment objectives, financial situation or particular needs before acting on such opinions or recommendations. This publication is not for public circulation or reproduction whether in whole or in part and is not to be disclosed to any person other than the intended recipient, without obtaining the prior written consent of Aegis. Aegis and/or each Participant, their officers, employees or its related bodies corporate may, from time to time hold positions in any securities included in this report and may buy or sell such securities or engage in other transactions involving such securities. Aegis and the Participants, their directors and associates declare that from time to time they may hold interests in and/or earn brokerage, fees or other benefits from the securities mentioned in this publication.

Aegis, its officers, employees and its related bodies corporate have not and will not receive, whether directly or indirectly, any commission, fee, benefit or advantage, whether pecuniary or otherwise in connection with making any statements and/or recommendation (if any), contained in this Report. Aegis discloses that from time to time it or its officers, employees and related bodies corporate may have an interest in the securities, directly or indirectly, which are the subject of these statements and/or recommendations (if any) and may buy or sell securities in the companies mentioned in this publication; may effect transactions which may not be consistent with the statements and/or recommendations (if any) in this publication; may have directorships in the companies mentioned in this publication; and/or may perform paid services for the companies that are the subject of such statements and/or recommendations (if any).

However, under no circumstances has Aegis been influenced, either directly or indirectly, in making any statements and/or recommendations (if any) contained in this Report.

The information contained in this publication must be read in conjunction with the Legal Notice which can be located at <http://www.aer.com.au>

Compumedics Limited (CMP)



Sector	Industry Group	Sub Industry	Disease Target
Medical Device	Health Care Equipment	Diagnostics	Sleep Disorders, Neurology Disorders, Brain Research

Company Overview

Compumedics Limited is a worldwide leader in the development and commercialisation of computer based medical technology. Its technology has so far focused on the fast growing, high value sleep medicine market though it is increasingly focusing on the associated fields of neurodiagnostics and brain research. By defining life's signals, Compumedic's technology turns vast amounts of data into valuable information that leads to more accurate diagnosis and consequently more effective therapy for some of the most serious health conditions.

Strategy

The Company's core business is the development and commercialisation of technology with a focus on the fast growing Sleep Medicine and Neurology markets. Compumedics is leveraging its existing technology to continue its expansion into a number of related market sectors including cardiac diagnostics, fatigue monitoring, in-depth anesthesia monitoring and sleep disorders therapy.

Key Executives

David Burton – Executive Chairman

David Burton, founder of Compumedics Ltd, received a Clunies Ross National Science and Technology Award for his development of innovative sleep monitoring technology in 2002. The following year, David was honoured as one of Victoria's most talented entrepreneurs, winning the Entrepreneur Of the Year for Technology, Communications, E-commerce and Life Sciences, Southern Region Australia.

Andrew Smith – Chief Operations Officer

David Lawson – Chief Financial Officer and Company Secretary

Warwick Freeman – Chief Technology Officer

Jeff Kuznia – VP Sales and Marketing, Americas

David Loiterton – General Manager Sales and Marketing, Australia, Asia, Europe

Key investment information

Market Cap: \$40.6M

Capital Structure (M)

Ord shares on issue: 140.0

Options (fully diluted): 5.0

Convertible notes/other: NIL

Price as at 09-Aug: \$0.29

12 month H/L: \$0.24 - \$0.48

Avg daily turnover: \$0.04M

Official listing date: Dec-00

Substantial Shareholders

D & DJ Burton Holdings Pty Ltd 62.7%

Teijin Limited 5.9%

NJI No. 2 Investment/C 4.9%

Cash Position

Cash (as at Dec-03): \$6.4M

Years with planned expenditure: N/A

Company contact



David Lawson

Chief Financial Officer & Company Secretary

dlawson@compumedics.com.au

61 3-8420 7300

www.compumedics.com

Main Company R&D Projects – Major Technology & Market

1: Compumedics Sleep Division

Target Market: Clinical Sleep : Sleep Laboratories/ Clinics, Respiratory Labs, Hospitals, Sleep Physicians, Research Institutions

Stage: Market

Innovation & first class industrial design distinguishes Compumedics (CMP) in the sleep field. The world's first wireless sleep diagnostic system, "Siesta" is used at renowned clinical & research sites globally. Being wireless allows versatility, efficiency & cost savings never available before. "Somté" records both cardiac & respiratory data that uniquely allows comprehensive analyses of the inter-related disorders of sleep & cardiology. "Somté" facilitates diagnosis in the home with its small size and enhanced ease of use. CMP has > 80% of the Australian sleep market with world recognised clients eg. the Austin & RPAH. Other prestigious clients incl. NASA, Nat. Inst. of Health (USA), the Mayo Clinic (USA), Mannheim Hosp. (GER) & Royal Edinburgh Infirmary (UK).

2: Compumedics Neuroscience Divisions

Target Market: Clinical Neurophysiology - EEG, EMG, Neurologists, Epileptologists, Research Institutions

Stage: Market

This division is devoted to brain and nerve diagnostics and has released a stream of market leading product innovations. "Safiro", an ambulatory, compact & affordable EEG system allows patients free to walk around while excellent quality monitoring & recording occurs. "Comperio", a leading edge diagnostic tool used for nerve & muscle conditions uses the unique "Decomposition Quantitative" protocol for increased speed of data acquisition & processing.

3: Compumedics Neuroscan Division

Target Market: Brain Research : Universities, Research Organisations, Research Hospitals

Stage: Market

This division grew out of the acquisition of Neuroscan two years ago. Its flagship product is "SynAmps2", considered to be the most powerful brain wave amplifier in the world, providing high speed, density and fidelity to a demanding high-end research market. SynAmps2 has active noise cancellation technology that can eliminate the time-consuming preparation stages saving time and scarce resources. SynAmps 2 has over 500 channels, offering far greater sensitivity and functionality. CMP Neuroscan equipment has been adopted by some of the world's premier research groups - Albert Einstein College of Med. (USA), Harvard Uni (USA), Oxford Uni (UK), Tokyo Uni. (Japan) and Beijing Lab of Cognitive Science (China).

Aegis Equities Comments

Market Position: CMP is an emerging leader of diagnostic technology for sleep and brain disorders. CMP's technology monitors cardio-respiratory patterns, brain waves or both. CMP's lab management software is a high value product that helps streamline sleep lab administration and record keeping. CMP's products are high-end, particularly in neuro-diagnostics, enabling sales beyond diagnostic labs and hospitals to academic research units.

Milestone Record: CMP continues to innovate in both sleep and neurology diagnostic lines. It won a sleep equipment contract at a major UK research institution in Oct 03. CMP's new generation brain research product (SynAmps 2) generated \$2.5M sales in its first 6 months on market in 1H04. CMP achieved NPAT of \$1.1M in 1H04, with strong margin improvement, cost reductions and working capital efficiencies.

Risk Profile: CMP's strong track record of technical innovation will need to continue to protect its growth prospects against well-resourced competitors, but CMP must also be careful not to over-extend itself with its product range. CMP is exposed to general economic conditions, as the screws inevitably tighten on hospital and academic capex budgets in downturns. With growing global sales, currency risks will increase, requiring effective hedging strategies

Compumedics Systems (Clockwise from top left) Siesta , SynAmps2 , Somte, Comperio DQ



Share price performance



Source: IRESS



Level 6, 33 York Street
Sydney NSW 2000 Australia
Locked Bag 7 Australia Square
Sydney NSW 1215
Phone 61 2 8296 1100
Fax 61 2 9299 3777
ABN 72 085 293 910
www.aer.com.au